



bonalive

Smart Healing

Literature references

Bonalive is a smart biomaterials company, transforming healthcare at the intersection of biology and technology. With over 20 years of clinical history, and one of the most evidence-based technologies in the industry, we are re-imagining a smarter future for healthcare.

Content

In vitro studies.....	4
Inhibition of bacterial growth.....	4
Bone regeneration.....	6
Other.....	7
Preclinical studies.....	8
Clinical studies.....	11
Bone infection.....	11
Trauma.....	12
Spine.....	13
Benign bone tumor.....	13
Mastoid.....	14
Oral and maxillofacial.....	14
Frontal sinus.....	16
Books.....	17
Scientific.....	17
Thesis.....	17
Level I and Level II clinical studies.....	18

Important literature references are marked with a symbol.



Access to abstracts and articles through hyperlinks.

IN VITRO

Inhibition of bacterial growth

BAG-S53P4 as bone graft extender and antimicrobial activity against gentamicin- and vancomycin-resistant bacteria.

Bortolin M, Romanò CL, Bidossi A, De Vecchi E, Mattina R, Drago L.
Future Microbiology. 2018 Apr;13(5):525-33.

In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection.

Cunha TM, Murça MA, Nigro S, Klautau GB, Salles MJC.
BMC Infectious Diseases. 2018;18:157. [Open access]

Recent evidence on bioactive glass antimicrobial and antibiofilm activity: a mini-review.

Drago L, Toscano M, Bottagisio.
M. Materials. 2018;11(2):326. [Open access]

Influence of bioactive glass S53P4 granules and putty on osteomyelitis associated bacteria in vitro.

Stoor P, Frantzen F. Biomed Glasses. 2017;3(1). [Open access]



Antibiofilm agents against MDR bacterial strains: is bioactive glass BAG-S53P4 also effective?

Bortolin M, De Vecchi E, Romanò CL, Toscano M, Mattina R and Drago L.
J Antimicrob Chemother 2016 Jan;71(1):123-7.

Bioactive glass combined with bisphosphonate provides protection against biofilms formed by the periodontal pathogen *Aggregatibacter actinomycetemcomitans*.

Hiltunen AK, Skogman ME, Rosenqvist K, Juvone H, Ihalainen P, Peltonen J, Juppo A, Fallalero A.
Int J Pharm 2016;501:211-20.



The antibacterial activity of bioactive glass.

Trishala A, Jacob C. International Journal of Advanced Research. 2016;4(6):1070-7. [Open access]



Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains.

Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R and Romanò CL.
Future Microbiol. 2015;10(8):1293-9.

Efficacy of antibacterial bioactive glass S53P4 against *S. aureus* biofilms grown on titanium discs in vitro.

Coraça-Huber DC, Fille M, Hausdorfer J, Putzer D, Noglen M. J Orthop Res. 2014;32(1):175-7. [Open access]



In vitro antibiofilm activity of bioactive glass S53P4.

Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romanò CL.
Future Microbiol. 2014;9(5):593-601.

The in vitro antibacterial effect of S53P4 bioactive glass and gentamicin impregnated polymethylmethacrylate beads.

Gergely I, Zazgyva A, Man A, Zuh SG, Pop TS. Acta Microbiol Immunol Hung. 2014;61(2):145-60.

IN VITRO

Inhibition of bacterial growth



Antibacterial effects and dissolution behavior of six bioactive glasses.

Zhang D, Leppäranta O, Munukka E, Ylänen H, Viljanen MK, Eerola E, et al.
J Biomed Mater Res. 2010;93A(2):475-83.



Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro.

Leppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Ylänen H, et al.
J Mater Sci: Mater Med. 2008;19:547-51.

Bactericidal effects of bioactive glasses on clinically important aerobic bacteria.

Munukka E, Leppäranta O, Korkeamäki M, Vaahtio M, Peltola T, Zhang D, et al.
J Mater Sci: Mater Med. 2008;19:27-32.

Factors controlling antibacterial properties of bioactive glasses.

Zhang D, Munukka E, Hupa L, Ylänen H, Viljanen MK, Hupa M.
Key Eng Mat. 2007;330-332:173-6.

Effect of ion release on antibacterial activity of melt-derived and sol-gel-derived reactive ceramics.

Vaahtio M, Munukka E, Leppäranta O, Zhang D, Eerola E, Ylänen H, Peltola T.
Key Eng Mat. 2006;309-311:349-52.

Comparison of antibacterial effect on three bioactive glasses.

Zhang D, Munukka E, Leppäranta O, Hupa L, Ylänen H, Salonen J, et al.
Key Eng Mat. 2006;309-311:345-8.

A comparative study on the disinfection potentials of bioactive glass S53P4 and calcium hydroxide in contra-lateral human premolars ex vivo.

Zehnder M, Luder H, Schätzle M, Kerosuo E, Waltimo T.
International Endodontic J. 2006;39(12):952-8.

Interactions between the bioactive glass S53P4 and the atrophic rhinitis-associated microorganism *Klebsiella ozaenae*.

Stoor P, Söderling E, Grenman R. J Biomed Mater Res. 1999;48:869-74.

Antibacterial effects of a bioactive glass paste on oral micro-organisms.

Stoor P, Söderling E, Salonen JI. Acta Odontol Scand. 1998;56:161-5.

Interactions between BAG and periodontal pathogens.

Stoor P, Kirstilä V, Söderling E, Kangasniemi I, Herbst K, Yli-Urpo A.
Microbial Ecology in Health and Disease. 1996;9:109-14.

Interactions between the frontal sinusitis-associated pathogen *Haemophilus Influenzae* and the bioactive glass S53P4.

Stoor P, Söderling E, Andersson OH, Yli-Urpo A. Bioceramics. 1995;8:253-8.

IN VITRO

Bone regeneration

Increase in VEGF secretion from human fibroblast cells by bioactive glass S53P4 to stimulate angiogenesis in bone.

Detsch R, Stoor P, Grünewald A, Roether JA, Lindfors NC, Boccaccini AR. *J Biomed Mater Res* 2014;102(11):4055-61.

Enhanced osteogenicity of bioactive composites with biomimetic treatment.

Meretoja V, Tirri T, Malin M, Seppälä J, Närhi T. *Biomed Res Int*. 2014;2014:207676. [Open access]

Evaluating optimal combination of clodronate and bioactive glass for dental application.

Rosenqvist K, Airaksinen S, Vehkamäki M, Juppo AM. *Int J Pharm*. 2014;1;468(1-2):112-20.

Interaction of bioactive glass with clodronate.

Rosenqvist K, Airaksinen S, Fraser S, Gordon K, Juppo AM. *Int J Pharm*. 2013;452:102-7.



Effects of bioactive glass S53P4 or beta-tricalcium phosphate and bone morphogenetic protein-2 and bone morphogenetic protein-7 on osteogenic differentiation of human adipose stem cells.

Waselau M, Patrikoski M, Juntunen M, Kujala K, Kääriäinen M, Kuokkanen H, Sándor GK, Vapaavuori O, Suuronen R, Mannerström B, von Rechenberg B, Miettinen S. *J Tissue Eng*. 2012;3(1).

Osteoblast response to continuous phase macroporous scaffolds under static and dynamic culture conditions.

Meretoja VV, Malin M, Seppälä JV, Närhi TO. *J Biomed Mater Res*. 2008;89A(2):317-25.

Bioactive glass induced in vitro apatite formation on composite GBR membranes.

Tirri T, Rich J, Wolke J, Seppälä J, Yli-Urpo A, Närhi T. *J Mater Sci: Mater Med*. 2008;19:2919-23.



Molecular basis for action of bioactive glasses as bone graft substitute.

Välimäki VV, Aro HT. *Scand J Surg*. 2006;95(2):95-102.

Intact surface of bioactive glass S53P4 is resistant to osteoclastic activity.

Wilson T, Parikka V, Holmbom J, Ylänen H, Penttinen R. *J Biomed Mater Res*. 2005;77A:67-74.

Surface porous fibre-reinforced composite bulk bone substitute - In vitro studies and in vivo evaluation in segment defect.

Aho A, Hautamäki M, Mattila R, Alander P, Strandberg N, Rekola J, Gunn J, Lassila LV, Vallittu PK. *Cell Tissue Bank* 2004;5:213-21.

Osteoblast differentiation of bone marrow stromal cells cultured on silica gel and sol-gel-derived titania.

Dieudonné SC, van den Dolder J, de Ruijter JE, Paldan H, Peltola T, van 't Hof MA, Happonen RP, Jansen JA. *Biomaterials*. 2002;23(14):3041-51.

Experimental follow-up model for clinical frontal sinus obliteration with bioactive glass (S53P4).

Peltola M, Suonpää J, Aitasalo K, Varpula M, Yli-Urpo A, Happonen R-P. *Acta Otolaryngol Suppl*. 2000;543:167-169.

In vitro model for frontal sinus obliteration with bioactive glass S53P4.

Peltola M, Suonpää J, Andersson Ö, Määttänen H, Aitasalo K, Yli-Urpo A, Laippala P. *J Biomed Mater Res*. 2000;53:161-6.



Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing.

Virolainen P, Heikkilä J, Yli-Urpo A, Vuorio E, Aro HT. *J Biomed Mater Res*. 1997;35A(1):9-17.

IN VITRO

Other studies

Composition dependent mechanical behaviour of S53P4 bioactive glass putty for bone defect grafting.

van Gestel N, Hulsen D, Geurts J, Hofmann S, Ito K, Arts J, van Rietbergen B. J Mech Behav Biomed Mat. 2017;69:301-6.

Mechanical behaviour of bioactive glass granules and morselized cancellous bone allograft in load bearing defects.

Hulsen DJW, Geurts J, van Gestel NAP, van Rietbergen B, Arts JJ. J Biomech. 2016;49:1121-7.

Compression properties and dissolution of bioactive glass S53P4 and n-butyl-2 cyanoacrylate tissue adhesive-composite.

Sarin J, Hiltunen M, Hupa L, Pulkkinen J, Vallittu PK. Biomed Mater Eng. 2016 Sep 28;27(4):425-36.

The effect of fibrin sealant on bioactive glass S53P4 particles — pH impact and dissolution characteristics in vitro.

Sarin J, Björkvik L, Hiltunen M, Hupa L, Pulkkinen J, Vallittu PK. J Sci: Adv Mater Dev. 2016;482-87. [Open access]

BAG-S53P4 as an additive to bone allografts: A laboratory study using an uniaxial compression test.

Putzer D, Coraça-Huber D, Ammann C, Liebensteiner M, Nogler M. J Orthop Res. 2015;33(12):1875-9. [Open access]

Dissolution patterns of biocompatible glasses in 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris) buffer.

Fagerlund S, Hupa L, Hupa M. Acta Biomater. 2013;9:5400-10.

Review of bioactive glass: From Hench to hybrids.

Jones J. Acta Biomater. 2013;9(1):4457-86.

Crystallization mechanism of the bioactive glasses, 45S5 and S53P4.

Massera J, Fagerlund S, Hupa L, Hupa M. J Am Ceram Soc. 2012;95(2):607-13.

Surface reactions of bioactive glasses in buffered solutions.

Varila L, Fagerlund S, Lehtonen T, Tuominen J, Hupa L. J Europ Cer Soc. 2012;32:2757-63.

Load bearing capacity of bone anchored fiber-reinforced composite device.

Ballo AM, Lassila L, Vallittu P, Närhi T. J Mater Sci: Mater Med. 2007;18: 2025-31.

In situ pH within particle beds of bioactive glasses.

Zhang D, Hupa M, Hupa L. Acta Biomaterialia. 2008;4(5):1498-505.

Immunoglobulin enhances the bioactive-glass-induced chemiluminescence response of human polymorphonuclear leukocytes.

Lindfors N.C, Klockars M. J Biomed Mater Res. 2001 Jun 15;55(4):613-7.

Protein adsorption to bioactive glasses with special reference to precorrosion.

Söderling E, Herbst K, Larmas E, Yli-Urpo A. J Biomed Mater Res. 1996;31:525-31.

PRECLINICAL



Bone morphogenic protein expression and bone formation are induced by bioactive glass S53P4 scaffolds in vivo.

Björkenheim R, Strömberg G, Ainola M, Uppstu P, Aalto-Setälä L, Hupa L, Pajarinen J, Lindfors NC. *J Biomed Mater Res B Appl Biomater*. 2018 Sep 8. doi: 10.1002/jbm.b.34181. [In print].



Polymer-coated bioactive glass S53P4 increases VEGF and TNF expression in an induced membrane model in vivo.

Björkenheim R, Strömberg G, Pajarinen J, Ainola M, Uppstu P, Hupa L, Böhling TO, Lindfors NC. *J Mater Sci* 2017;52(15):9055-65.



BAG S53P4 putty as bone graft substitute – a rabbit model.

Saarenpää I, Stoor P, Frantzén J. *Biomed Glasses*. 2017;3(1):30-40.

Bioactive glass in cavitory bone defects: a comparative experimental study in rabbits.

Camargo AFF, Baptista AM, Natalino R, Camargo OP. *Acta Orthop Bras*. 2015;23(4):202-7. [Open access]

S53P4 bioactive glass and fibrin glue for the treatment of osteochondral lesions of the knee – a preliminary in vivo study in rabbits.

Zazgyva A, Gurzu S, Jung I, Nagy Ö, Mühlfay G, Pop T. *Rom. J Morphol Embryol*. 2015;56(3):1085-90. [Open access]

Comparison of the osteoconductive properties of three particulate bone fillers in a rabbit model: Allograft, calcium carbonate (Biocoral®) and S53P4 bioactive glass.

Gunn J.M, Rekola J, Hirvonen J, Aho A. *Acta Odontologica Scandinavica*. 2013;71(5):1238-42.

Hydroxyapatite coating of cellulose sponges attracts bone-marrow-derived stem cells in rat subcutaneous tissue.

Tommila M, Jokilampi A, Terho P, Wilson T, Penttinen R, Ekholm E. *J R Soc Interface*. 2009;6:873-80. [Open access]

Bioactive glass-derived hydroxyapatite-coating promotes granulation tissue growth in subcutaneous cellulose implants in rats.

Tommila M, Jokinen J, Wilson T, Forsback A-P, Saukko P, Penttinen R, Ekholm E. *Acta Biomaterialia*. 2008;4:354-61.

Mechanical verification of soft-tissue attachment on bioactive glasses and titanium implants.

Zhao D, Mortiz N, Vedel E, Hupa L, Aro H. *Acta Biomaterialia*. 2008;4(4):1118-22.

Bioactive glass granules as extender of autogenous bone grafting in cementless intercalary implant of the canine femur.

Keränen P, Itälä A, Koort J, Kohonen I, Dalstra M, Kommonen B, Aro H. *Scand J Surg*. 2007;96(3):243-51.

In vivo behavior of poly/bioactive glass composites in rat.

Ranne T, Tirri T, Yli-Urpo A, Närhi T, Laine V, Rich J, Seppälä J, Aho A. *J Bioactive Compatible Polymers*. 2007;22(3):249-64.

Frontal bone defect repair with experimental glass-fiber-reinforced composite with bioactive glass granule coating.

Tuusa S, Peltola M, Tirri T, Lassila L, Vallittu P. *J Biomed Mater Res*. 2007;82B:149-55.

Injectable bioactive glass biodegradable polymer composite for bone and cartilage reconstruction: Concept and experimental outcome with thermoplastic composites of poly and bioactive glass.

Aho A, Tirri T, Kukkonen J, Strandberg N, Rich J, Seppälä J, Yli-Urpo A. *J Mater Sci: Mater Med*. 2004;15(10):1165-73.

PRECLINICAL

Granule size and composition of bioactive glasses affect osteoconduction in rabbit.

Lindfors NC, Aho AJ. *J Mater Sci: Mater Med.* 2003;14(4):265-372.

Bone response to degradable thermoplastic composite in rabbits.

Närhi T, Jansen J, Jaakkola T, de Ruijter A, Rich J, Seppälä J, Yli-Urpo A. *Biomaterials.* 2003;24(10):1697-704.

Frontal sinus and skull bone defect obliteration with three synthetic bioactive materials. A comparative study.

Peltola M, Aitasalo KM, Suonpää JT, Yli-Urpo A, Laippala PJ, Forsback A. *J Biomed Mater Res B Appl Biomater.* 2003;66(1):364-72.

Comparison of bioactive glass, mineral trioxide aggregate, ferric sulfate, and formocresol as pulpotomy agents in rat molar.

Salako N, Joseph B, Ritwik P, Salonen J, John P, Junaid TA. *Dental Traumatology.* 2003;19(6):314-20.

Bioactive glass as bone-graft substitute for posterior spinal fusion in rabbit.

Lindfors NC, Tallroth K, Aho AJ. *J Biomed Mater Res.* 2002;63(2):237-44.

Bioactive glass in frontal sinus and skull bone defect obliteration.

Peltola M, Aitasalo K, Suonpää J, Yli-Urpo A. *Key Eng Mat.* 2001;192-195:937-40.

In vivo model for frontal sinus and calvarial bone defect obliteration with bioactive glass S53P4 and hydroxyapatite.

Peltola MJ, Aitasalo KM, Suonpää JT, Yli-Urpo A, Laippala PJ. *J Biomed Mater Res.* 2001;58(3):261-9.

Pre-treated bioactive composite in rat soft tissue.

Tirri T, Jaakkola T, Närhi T, Rich J, Seppälä J, Yli-Urpo A. *Key Eng Mat.* 2001;192-195:653-6.

Tissue response to bioactive glass and autogenous bone in the rabbit spine.

Lindfors NC, Aho AJ. *Eur Spine J.* 2000;9(1):30-5. [Open access]

Bioactive glass granules and polytetrafluoroethylene membrane in the repair of bone defects adjacent to titanium and bioactive glass implants.

Turunen T, Peltola J, Makkonen T, Helenius H, Yli-Urpo A, Happonen R-P. *J Mater Sci: Mater Med.* 1998;9(7):403-7.

Bioactive glass and calcium carbonate granules as filler material around titanium and bioactive glass implants in the medullar space of the rabbit tibia.

Turunen T, Peltola J, Helenius H, Yli-Urpo A, Happonen, R. *Clin Oral Impl Res.* 1997;8(2):96-102.

Transmission electron microscopy at the interface between S53P4 and bone.

Aho AJ, Heikkilä JT, Aho HJ, Yli-Urpo A. *Bioceramics.* 1996;9:41-4.

Long term behaviour of bioactive glass cone and granules in rabbit bone.

Heikkilä JT, Salonen H, Yli-Urpo A, Aho AJ. *Bioceramics.* 1996;9:123-6.

Protein adsorption properties of bioactive glasses compared to their behaviour in rabbit tibia.

Brink M, Söderling E, Turunen T, Karlsson KH. *Bioceramics.* 1995;8:471-6.

Influence of granule size on the reactions of a bioactive glass for repair of bone defects.

Gatti A, Andersson Ö, Valdre G, Chiarini L, Tanza D, Bulgarelli S, Monari E. *Materials in Clinical Applications.* 1995:409-16.



PRECLINICAL

Bone formation in rabbit cancellous bone defects filled with bioactive glass granules.

Heikkilä J, Aho H, Yli-Urpo A, Happonen R, Aho A. *Acta Orthop Scand*. 1995;66(5):463-7. [Open access]

Bone growth into surgically created cavities implanted with glass granules.

Lindfors NC, Slätis P, Karlsson K, Andersson Ö. *Bioceramics*. 1995;8:107-11.

Effect of bioactive glass granules and polytetrafluoroethylene membrane on repair of cortical bone defect.

Turunen T, Peltola J, Happonen R-P, Yli-Urpo A.

Journal of Materials Science: Materials in Medicine. 1995;6(11):639-41.

Augmentation of the maxillary sinus wall using bioactive glass and autologous bone.

Turunen T, Peltola J, Kangasniemi I, Jussila J, Uusipaikka E, Yli-Urpo A, Happonen R-P.

Bioceramics. 1995;8:259-64.

Short term reaction kinetics of bioactive glass in simulated body fluid and in subcutaneous tissue.

Andersson Ö, Vähätalo K, Yli-Urpo A, Happonen R-P, Karlsson K. *Bioceramics*. 1994;7:67-72.

Analysis of the in vivo reactions of a bioactive glass in soft and hard tissue.

Gatti A, Valdrè G, Andersson Ö. *Biomaterials*. 1994;15(3):208-12.

Effect of glass bioactivity on new bone development induced by demineralized bone matrix in a rat ex-traskeletal site.

Pajamäki K, Andersson Ö, Lindholm T, Karlsson K, Yli-Urpo A, Laippala P, Happonen R-P.

Acta Orthop Trauma Surg. 1994;113(4):210-4.

In-vivo reactions in some bioactive glasses and glass-ceramics granules.

Gatti A, Yamamuro T, Hench L, Andersson Ö. *Cells and Materials*. 1993;3(3):283-91.

Induction of new bone by allogeneic remineralized bone matrix compared to bioactive glass composite in the rat.

Pajamäki K, Andersson Ö, Lindholm T, Karlsson K, Yli-Urpo A, Happonen R-P.

Annales Chirurgiae et Gynecologiae. 1993;82:137-44.

Effect of bovine bone morphogenetic protein and bioactive glass on demineralized bone matrix grafts in the rat muscular pouch.

Pajamäki K, Andersson Ö, Lindholm T, Karlsson K, Yli-Urpo A, Happonen R-P.

Ann Chir Gynecol Suppl. 1993;82:155-61.

Short term surface reactions of a bioactive glass implanted subcutaneously in rat.

Happonen R-P, Vähätalo K, Yli-Urpo A, Andersson Ö. *Bioceramics*. 1992;5:185-90.

In vivo behaviour of glasses in the $\text{SiO}_2\text{-Na}_2\text{O-CaO-P}_2\text{O}_5\text{-Al}_2\text{O}_3\text{-B}_2\text{O}_3$ system.

Andersson Ö, Liu G, Karlsson K, Niemi L, Miettinen J, Juhanoja J.

Journal of Materials Science: Materials in Medicine. 1990;1(4):219-27.

CLINICAL

Bone infection surgery



The use of bioactive glass S53P4 as bone graft substitute in the treatment of chronic osteomyelitis and infected non-unions – a retrospective study of 50 patients.

Al Malat TA, Glombitza M, Dahmen J, Hax P-M, Steinhausen E. *Z Orthop Unfall* 2018;156:152-9.

Bioactive glass S53P4: a new opportunity for the treatment in the diabetic foot osteomyelitis.

De Giglio R, Stefani I, Mondello T, De Filippis G, Mazzone A. *Eur J Intern Med.* 2018 Aug;54:e15-e16.

Contemporary treatment of chronic osteomyelitis: implementation in low- and middle-income countries.

Geurts J, Vranken T, Gabriels F, Arts JJ, Moh P. *SA Orthop J.* 2018;17(2):40-3. [Open access]



Evaluation of the clinical effectiveness of bioactive glass (S53P4) in the treatment of non-unions of the tibia and femur: study protocol of a randomized controlled non-inferiority trial.

Tanner MC, Heller R, Westhauser F, Miska M, Ferbert T, Fischer C, Gantz S, Schmidmaier G, Haubruck P. *Trials.* 2018;19(1):299. [Open access]

Treatment of cavitory bone defects in chronic osteomyelitis: Bioactive glass S53P4 vs. calcium sulphate antibiotic beads.

Ferrando A, Part J, Baeza J. *Journal of Bone and Joint Infection* 2017;2(4):194-201. [Open access]

Il trattamento delle pseudoartrosi settiche di tibia con la tecnica di Ilizarov isolata o associata a biovetro attivo. *Treatment of infected tibial nonunions with Ilizarov technique and bioactive glass.*

Testa G, Aloj DC, Pavone V, Massè A, Avondo S, Sessa G. *Giornale Italiano di Ortopedia e Traumatologia* 2017;43:251-7.



Antibacterial bioactive glass, S53P4, for chronic bone infections - a multinational study.

Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, Suda A, Domenico A, Artiaco S, Alizadeh C, Brychcy A, Bialecki J, Romano C. *Adv Exp Med Biol* 2017;971:81-92.

Treatment of osteomyelitis by means of bioactive glass – initial experience in the Netherlands.

Geurts J, Vranken T, Arts CJJ. *Nederlands Tijdschrift voor Orthopaedie.* 2016;23(2):37-41. [Open access]

Two-stage treatment for infected nonunion of the humerus: a case report.

Puma Pagliarello C, Testa G, Lombardini A, Condorelli G, Pavone V. *Infec Dis Trop Med* 2016;3(2):E390. [Open access]

Clinical application of antimicrobial bone graft substitute in osteomyelitis treatment: A systematic review of different bone graft substitutes available in clinical treatment of osteomyelitis.

van Vugt T, Geurts J, Arts J. *Biomed Res Int.* 2016;2016:6984656. [Open access]

Bioactive glass for long bone infection: a systematic review.

Aurégan J, Bégué T. *Injury, Int. J. Care Injured.* 2015;46(8):3-7.

New trends in surgical treatment of chronic osteomyelitis.

Juutilainen V, Lindfors NC. *Suomen Ortopedia ja Traumatologia.* 2015;38:59-61. [Open access]

Clinical applications of S53P4 bioactive glass in bone healing and osteomyelitic treatment: A literature review.

van Gestel N, Geurts J, Hulsen D, van Rietbergen B, Hofmann S, Arts J. *BioMed Research International.* 2015;2015: 684826. [Open access]

CLINICAL

Bone infection surgery



Review: Emerging developments in the use of bioactive glasses for treating infected prosthetic joints.
Rahaman M, Bal BS, Huang W. Mater Sci Eng C Mater Biol Appl. 2014;C41:224-31.

A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis - a retrospective comparative study.
Romanò CL, Logoluso N, Meani E, Romanò D, De Vecchi E, Vassena C, Drago L.
Bone Joint J 2014;96-B:845-50.

Bioactive glass BAG-S53P4 for the adjunctive-treatment of chronic osteomyelitis of the long bones: An in vitro and prospective clinical study.
Drago L, Vassena C, Fenu S, De Vecchi E. BMC Infectious Diseases. 2013;13:584. [Open access]

Through the looking glass; bioactive glass S53P4 (BonAlive®) in the treatment of chronic osteomyelitis.
McAndrew J, Efrimescu C, Sheehan E, Niall D. Ir J Med Sci. 2013;182(3):509-11.

Posttraumatic osteomyelitis.
Juutilainen V. Suomen Ortopedia ja Traumatologia 2011;34:38-41. [Open access]

Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis.
Lindfors NC. Bone. 2010;47:212-18.

Trauma surgery

Our short-term experience with the use of S53P4 (BonAlive®) bioactive glass as a bone graft substitute.
Gergely I, Zazgyva A, Man A, Zuh SG, Pop TS. Acta Medica Marisiensis. 2011;57(6):627-30. [Open access]



Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study.
Heikkilä J, Aho H, Yli-Urpo A, Happonen R-P, Aho A. J Mater Sci: Mater Med. 2011;22(4):1073-80.



Bioactive glass S53P4 and autograft bone in treatment of depressed tibial plateau fractures. A prospective randomized 11- year follow-up.
Perna K, Koski I, Mattila K, Gullichsen E, Heikkilä J, Aho A.
J Long-term Eff Med Impl. 2011;21(2):139-48.

CLINICAL

Spine surgery

Reconstruction of vertebral bone defects using an expandable replacement device and bioactive glass S53P4 in the treatment of vertebral osteomyelitis: Three patients and three pathogens.

Kankare J, Lindfors NC. Scandinavian Journal of Surgery. 2016;105(4):248-53.

Posterolateral spondylodesis using bioactive glass S53P4 and autogenous bone in instrumented unstable lumbar spine burst fractures. A prospective 10-year follow-up study.

Rantakokko J, Frantzen J, Heinänen J, Kajander S, Kotilainen E, Gullichsen E, Lindfors NC. Scan J Surg. 2012;101(1):66-71.

Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone. A prospective 11-year follow-up.

Frantzen J, Rantakokko J, Aro H, Heinänen J, Kajander S, Gullichsen E, Kotilainen E, Lindfors NC. J Spinal Disorder Tech. 2011;24(7):455-61.

Benign bone tumor surgery



Treatment of aneurysmal bone cysts with bioactive glass in children.

Syvänen J, Nietosvaara Y, Kohonen I, Koskimies E, Haara M, Korhonen J, Pajulo O, Helenius I. Scand J Surg 2017;1-6.

S53P4 bioactive glass - an alternative treatment of bone defects.

Trambitas C, Pop TS, Miron ADT, Dorobantu DC, Brinzaniuc K. Revista De Chimie 2017;68(2):387-9. [Open access]

Clinical experience on bioactive glass S53P4 in reconstructive surgery in the upper extremity showing bone remodelling, vascularization, cartilage repair and antibacterial properties of S53P4.

Lindfors NC. J Biotech Biomat. 2011;1(5). [Open access]



A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumours.

Lindfors NC, Aho A. J Biomed Mater Res. 2010;94B(1):157-64.

Treatment of a recurrent aneurysmal bone cyst with bioactive glass in a child allows for good bone remodeling and growth.

Lindfors NC, Aho A. Bone. 2009;45:398-400.

Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors.

Lindfors NC, Heikkilä J, Aho A. J Biomed Mater Res. 2009,90B(1),131-6.

Long-term evaluation of blood silicon and osteocalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone.

Lindfors NC, Heikkilä J, Koski I, Mattila K, Aho A. J Biomed Mater Res. 2008,87B(1):73-6.

Behavior of bioactive glass in human bone.

Heikkilä J, Salonen H-R, Yli-Urpo A, Aho A. Bioceramics. 1995;8:35-40.

CLINICAL

Mastoid surgery



Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass S53P4: a prospective clinical study.

Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, Nguyen Y, Sterkers O. Clin Otolaryngol. 2017;42(2):387-96.



Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery.

de Veij Mestdagh P, Colnot D, Borggreven P, Orelino C, Quak J. Acta Oto-Laryngologica 2017;137(7):690-94.



Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.

Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelino C, Quak J. Eur Arch Otorhino-laryngol. 2017;274(12):4121-26.



Cutaneous and labyrinthine tolerance of bioactive glass S53P4 in mastoid and epitympanic obliteration surgery: prospective clinical study.

Bernardeschi D, Nguyen Y, Mosnier I, Smail M, Sterkers O. BioMed Research International. 2015:1-6.

Obliteration von Mastoidhöhlen.

Schimanski G, Schimanski E. HNO. 2015;63(8):538-45.

Bioactive glass S53P4 in mastoid obliteration surgery for chronic otitis media and cerebrospinal fluid leakage.

Sarin J, Grénman R, Aitasalo K, Pulkkinen J. Annals of Otolaryngology, Rhinology & Laryngology. 2012;121(9):563-9.

Mastoidectomy cavity obliteration with bioactive glass: a pilot study.

Silvola JT. Otolaryngology - Head and Neck Surgery. 2012;147(1):119-26.

Bioactive glass S53P4 in the filling of cavities in the mastoid cell area in surgery for chronic otitis media.

Stoor P, Kirstilä V, Söderling E, Kangasniemi I, Herbst K, Yli-Urpo A. Annals of Otolaryngology, Rhinology & Laryngology. 2010;119(6):377-82.

Oral and cranio maxillofacial surgery



Osteotomy site grafting in bilateral sagittal split surgery with bioactive glass S53P4 for skeletal stability.

Stoor P, Apajalahti S, Kontio R. J Craniofac Surg. 2017 Oct;28(7):1709-16.



Regeneration of cystic bone cavities and bone defects with bioactive glass S53P4 in the upper and lower jaws.

Stoor P, Apajalahti S, Kontio R. J Craniofac Surg. 2017 Jul;28(5):1197-205.

Bioactive-glass in oral and maxillofacial surgery.

Profeta AC, Huppa C. Craniomaxillofac Trauma Reconstr. 2016;9(1):1-14. [Open access]

CLINICAL

Oral and cranio maxillofacial surgery

The use of anatomically drop-shaped bioactive glass S53P4 implants in the reconstruction of orbital floor fractures. A prospective longterm follow-up study.

Stoor P, Mesimäki K, Lindqvist C, Kontio R. J Craniomaxillofac Surg. 2015;43(6):969-75.

Adipose stem cells used to reconstruct 13 cases with cranio-maxillofacial hard-tissue defects.

Sándor G, Numminen J, Wolff J, Thesleff T, Miettinen A, Tuovinen V, Mannerström B, Patrikoski M, Seppänen R, Miettinen S, Rautiainen M, Öhman J. Stem Cells Trans Med. 2014;3(4):530-40. [Open access]

Craniofacial bone reconstruction with bioactive fiber-reinforced composite implant.

Aitasalo K, Piitulainen J, Rekola J, Vallittu P. Head Neck. 2014;36(5):722-8.

Novel composite implant in craniofacial bone reconstruction.

Peltola M, Vallittu P, Vuorinen V, Aho A, Puntala A, Aitasalo K. Eur Arch Otorhinolaryngol. 2012;269(2):623-8. [Open access]

Reconstruction of orbital wall defects with bioactive glass plates.

Peltola M, Kinnunen I, Aitasalo K. J Oral Maxillofac Surg. 2008;66(4):639-46.

Long-term tissue reactions of three biomaterials in craniofacial surgery.

Peltola M, Aitasalo K, Tirri T, Rekola J, Puntala A. Key Engineering Materials. 2008;361-363:1343-6.

Bioactive glass hydroxyapatite in fronto-orbital defect reconstruction.

Aitasalo K, Peltola M. Plast Reconstr Surg. 2007;120(7):1963-72.

Bioaktiivinen lasi - suomalaista tutkimusta ja tuotekehitystä.

Peltola M. Erikoislääkäri. 2007;5:211-4.

Bioactive glass granules as a bone adjunctive material in maxillary sinus floor augmentation.

Turunen T, Peltola J, Yli-Urpo A, Happonen R. Clin Oral Impl Res. 2004;15(2):135-41.

Bioaktiivinen lasi pään ja kaulan alueen kirurgiassa.

Aitasalo K, Peltola M. Duodecim. 2004;120:1986-93.

Bioactive glass and turbinate flaps in the repair of septal perforations.

Stoor P, Grénman R. Ann Otol Rhinol. 2004;113(8):655-61.

Repair of orbital floor fractures with bioactive glass implants.

Aitasalo K, Kinnunen I, Palmgren J, Varpula M. J Oral Maxillofac Surg. 2001;59:1390-5.

Bioactive glass S53P4 in repair of septal perforations and its interactions with the respiratory infection-associated microorganisms *Haemophilus influenzae* and *Streptococcus pneumoniae*.

Stoor P, Söderling E, Grénman R. J Biomed Mater Res. 2001;58:113-20.

Reconstruction of orbital floor fractures using bioactive glass.

Kinnunen I, Aitasalo K, Pöllönen M, Varpula M. J Craniomaxillofac Surg. 2000;28, 229-34.

Bioactive glass granules and plates in the reconstruction of defects of the facial bones.

Suominen E, Kinnunen J. Scand J Plast Reconstr Surg Hand Surg. 1996;30(4):281-9.

CLINICAL

Oral and cranio maxillofacial surgery

Augmentation of the maxillary sinus wall using bioactive glass and autologous bone.

Turunen T, Peltola J, Kangasniemi I, Jussila J, Uusipaikka E, Yli-Urpo A, Happonen R-P. *Bioceramics*. 1995;8:259-64.

Frontal sinus surgery

Long-term microscopic and tissue analytical findings for 2 frontal sinus obliteration materials.

Peltola M, Aitasalo K, Aho AJ, Tirri T, Suonpää J. *J Oral Maxillofac Surg*. 2008;66(8):1699-707.

Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience.

Peltola M, Aitasalo K, Suonpää J, Varpula M, Yli-Urpo A. *Head and Neck*. 2006;28(9):834-41.

Bioactive glass S53P4 in frontal sinus obliteration. A 9-year experience.

Aitasalo K, Peltola M, Suonpää J, Yli-Urpo A. *Key Engineering Materials*. 2001;192-195:877-80.

Clinical follow-up method for frontal sinus obliteration with bioactive glass S53P4.

Peltola M, Suonpää J, Määttänen H, Varpula M, Aitasalo K, Yli-Urpo A, Laippala P. *J Biomed Mater Res*. 2001;58(1):54-60.

Experimental follow-up model for clinical frontal sinus obliteration with bioactive glass (S53P4).

Peltola M, Suonpää J, Aitasalo K, Määttänen H, Andersson Ö, Yli-Urpo A, Laippala P. *Acta Otolaryngol*. 2000;543:167-9.

Obliteration of the frontal sinus cavity with bioactive glass.

Peltola M, Suonpää J, Aitasalo K, Varpula M, Yli-Urpo A, Happonen R. *Head and Neck*. 1998;20(4):315-9.

Behaviour of bioactive glass (S53P4) in human frontal sinus obliteration.

Aitasalo K, Suonpää J, Peltola M, Yli-Urpo A. *Bioceramics*. 1997;10:429-32.

Obliteration of frontal sinuses with bioactive glass after chronic suppurative sinusitis.

One year follow up.

Aitasalo K, Peltola M, Suonpää J, Yli-Urpo A, Andersson Ö, Varpula M, Happonen R. *Bioceramics*. 1994;7:409-14.



BOOKS

Scientific

Bioactive glasses - materials, properties and applications.

Ylänen H. Bioactive Glasses, 2nd Edition. Woodhead Publishing Limited, UK. 2017.

Bioactive glasses in Infection treatment.

Lindfors N, Romanò C, Scarponi S, Lorenzo D, Bortolin M, Frantzén J, de Veij Mestdagh P, Colnot D, Borggreven P, Quak J. In: Boccaccini A, Brauer D, Hupa L. Bioactive Glasses: Fundamentals, Technology and Applications Smart Materials Series. Royal Society of Chemistry, Cambridge, UK. 2016;316-335.

S53P4 bioactive glass.

Arts JJC, Geurts J. In: Management of Periprosthetic Joint Infections (PJIs), 1st Edition. Woodhead Publishing Series in Biomaterials. 2016;69-81.

Mastoid cavity obliteration with bioactive glass granules.

Schimanski G, Schimanski E. In: Lalwani A, Pfister M. Recent Advances in Otolaryngology - Head and Neck Surgery. 2016;5:249-81.

Bone substitutes and related materials in clinical orthopaedics.

Aho A, Heikkilä J. In: Phillips GO. Clinical applications of bone allografts and substitutes biology and clinical applications. World Scientific Publishing. 2005;3:139-74.

Thesis

Factors affecting accuracy and fusion rate in lumbosacral fusion surgery. A preclinical and clinical study.

Saarenpää I. University of Turku. Turku, Finland. Thesis 2018.

Biomaterials in infection treatment.

Geurts J. Maastricht University. Maastricht, the Netherlands. Thesis 2018. [Open access]

Bioactive glass S53P4 and tissue adhesives in the surgical treatment of chronic middle ear and mastoidal infections.

Sarin J. University of Turku. Turku, Finland. Thesis 2017. [Open access]

Bioactive glass in lumbar spondylodesis. A preclinical and clinical study.

Frantzén J. University of Turku. Turku, Finland. Thesis 2012. [Open access]

Self-reinforced poly (desamino tyrosyl-tyrosine ethyl ester carbonate) and poly (LDL) lactide rods alone and with bioactive glass in the fixation of distal femoral osteotomies. An experimental study on rats and rabbits.

Pyhältö T. University of Helsinki and Helsinki University Central Hospital and from the Institute of Biomaterials, Tampere University of Technology. Helsinki, Finland. Thesis 2005. [Open access]

Interactions between oral and nasal microorganisms and the bioactive glass S53P4 with special reference to nasal cavity surgery.

Stoor P. University of Turku. Turku, Finland. Thesis 2001.

LEVEL I & LEVEL II CLINICAL STUDIES

USPSTF (The U.S. Preventive Services Task Force) is an independent panel of experts that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services.

Level I clinical studies

Properly powered and conducted RCT; well-conducted systematic review or meta-analysis of homogeneous RCTs. ^[1]

- **Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study.**
Heikkilä JT, Kukkonen J, Aho A, Moisander S, Kyrrönen T, Mattila K. *J Mater Sci: Mater Med.* 2011;22(4):1073-80. * / **
- **Bioactive glass S53P4 and autograft bone in treatment of depressed tibial plateau fractures. A prospective randomized 11-year follow-up.**
Perna K, Koski I, Mattila K, Gullichsen E, Heikkilä J, Aho A, Lindfors N. *J Long-term Eff Med Impl.* 2011;21(2):139-48. * / **
- **Bioactive glass and autogenous bone as bone graft substitutes in benign tumors.**
Lindfors NC, Heikkilä JT, Koski I, Mattila K, Aho A. *J Biomed Mater Res* 2009;90(1):131-6. * / ***
- **Long-term evaluation of blood silicon and osteocalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone.**
Lindfors NC, Heikkilä JT, Aho A. *J Biomed Mater Res* 2008;87(1):73-6. * / ***
- **A prospective randomized 14-year follow-up study of bioactive glass and autogenous**
Lindfors NC, Koski I, Heikkilä JT, Mattila K, Aho A. *J Biomed Mater Res.* 2010(a);94B(1):157-64. * / ***
- **Behavior of bioactive glass in human bone.**
Heikkilä JT, Mattila KT, Andersson ÖH, Knuuti J, Yli-Urpo A, Aho A. In: J. Wilson, L. Hench, D. Greenspan (eds). *Bioceramics*, Oxford: Elsevier Science. 1995;8:35-40. * / ***

Level II-1 clinical studies

Well-designed controlled trial without randomization. ^[1]

- **Treatment of cavitary bone defects in chronic osteomyelitis: Bioactive glass S53P4 vs. calcium sulphate antibiotic beads.**
Ferrando A, Part J, Baeza J. *J. Bone Joint Infect.* 2017;2(4):194-201.
- **A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium based bone substitutes in the treatment of chronic osteomyelitis. A retrospective comparative study.**
Romano CL, Logoluso N, Meani E, Romano D, De Vecchi E, Vassena C, Drago L. *The British Editorial Society of Bone & Joint Surgery.* 2014;96B(5):845-50.
- **Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.**
Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelia C, Quak J. *Eur Arch Otorhino-laryngol.* 2017;274(12):4121-6.

^[1] [Uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/). (2018). Section 4. Evidence Review Development - US Preventive Services Task Force. [online] Available at: <https://www.uspreventiveservicestaskforce.org/Page/Name/section-4-evidence-review-development>. [Accessed Oct 4, 2018]

* Power-calculation not documented
** Publications are from the same clinical study
*** Publications are from the same clinical study

